These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 23938063)

  • 1. The pathologic response of resected synovial sarcomas to hyperthermic isolated limb perfusion with melphalan and TNF-α: a comparison with the whole group of resected soft tissue sarcomas.
    Schwindenhammer B; Podleska LE; Kutritz A; Bauer S; Sheu SY; Taeger G; Schmid KW; Grabellus F
    World J Surg Oncol; 2013 Aug; 11(1):185. PubMed ID: 23938063
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan in patients with locally advanced soft tissue sarcomas: treatment response and clinical outcome related to changes in proliferation and apoptosis.
    Plaat BE; Molenaar WM; Mastik MF; Koudstaal J; van den Berg E; Koops HS; Hoekstra HJ
    Clin Cancer Res; 1999 Jul; 5(7):1650-7. PubMed ID: 10430064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of P-glycoprotein, multidrug resistance-associated protein 1, and lung resistance-related protein in human soft tissue sarcomas before and after hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan.
    Komdeur R; Plaat BE; Hoekstra HJ; Molenaar WM; Hollema H; van den Berg E; Mastik MF; van der Graaf WT
    Cancer; 2001 May; 91(10):1940-8. PubMed ID: 11346877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overexpression of the drug resistance-associated protein metallothionein does not correlate with response of sarcomas to isolated limb perfusion treatment.
    Grabellus F; Sheu SY; Tötsch M; Lehmann N; Kaiser GM; Jasani B; Taeger G; Schmid KW
    J Surg Oncol; 2010 May; 101(6):465-70. PubMed ID: 20401916
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Feasibility and efficacy of external beam radiotherapy after hyperthermic isolated limb perfusion with TNF-alpha and melphalan for limb-saving treatment in locally advanced extremity soft-tissue sarcoma.
    Olieman AF; Pras E; van Ginkel RJ; Molenaar WM; Schraffordt Koops H; Hoekstra HJ
    Int J Radiat Oncol Biol Phys; 1998 Mar; 40(4):807-14. PubMed ID: 9531364
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyperthermic isolated limb perfusion with tumour necrosis factor-alpha and melphalan as palliative limb-saving treatment in patients with locally advanced soft-tissue sarcomas of the extremities with regional or distant metastases. Is it worthwhile?
    Olieman AF; van Ginkel RJ; Molenaar WM; Schraffordt Koops H; Hoekstra HJ
    Arch Orthop Trauma Surg; 1998; 118(1-2):70-4. PubMed ID: 9833110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hyperthermic isolated limb perfusion with tumour necrosis factor and melphalan as treatment of locally advanced or recurrent soft tissue sarcomas of the extremities.
    Schraffordt Koops H; Eggermont AM; Liènard D; Kroon BB; Hoekstra HJ; van Geel AN; Nieweg OE; Lejeune FJ
    Radiother Oncol; 1998 Jul; 48(1):1-4. PubMed ID: 9756165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hyperthermic isolated limb perfusion in locally advanced soft tissue sarcoma and progressive desmoid-type fibromatosis with TNF 1 mg and melphalan (T1-M HILP) is safe and efficient.
    Bonvalot S; Rimareix F; Causeret S; Le Péchoux C; Boulet B; Terrier P; Le Cesne A; Muret J
    Ann Surg Oncol; 2009 Dec; 16(12):3350-7. PubMed ID: 19830495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hyperthermic isolated limb perfusion in locally advanced limb soft tissue sarcoma: A 24-year single-centre experience.
    Rastrelli M; Campana LG; Valpione S; Tropea S; Zanon A; Rossi CR
    Int J Hyperthermia; 2016; 32(2):165-72. PubMed ID: 26608883
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radiotherapy for soft tissue sarcomas after isolated limb perfusion and surgical resection: essential for local control in all patients?
    Deroose JP; Burger JW; van Geel AN; den Bakker MA; de Jong JS; Eggermont AM; Verhoef C
    Ann Surg Oncol; 2011 Feb; 18(2):321-7. PubMed ID: 21049306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hyperthermic isolated limb perfusion for recurrent melanomas and soft tissue sarcomas: feasibility and reproducibility in a multi-institutional Hellenic collaborative study.
    Lasithiotakis K; Economou G; Gogas H; Ioannou C; Perisynakis K; Filis D; Kastana O; Bafaloukos D; Decatris M; Catodritis N; Frangia K; Papadakis G; Magarakis M; Tsoutsos D; Chrysos E; Chalkiadakis G; Zoras O
    Oncol Rep; 2010 Apr; 23(4):1077-83. PubMed ID: 20204294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial.
    Eggermont AM; Schraffordt Koops H; Liénard D; Kroon BB; van Geel AN; Hoekstra HJ; Lejeune FJ
    J Clin Oncol; 1996 Oct; 14(10):2653-65. PubMed ID: 8874324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term results of tumor necrosis factor alpha- and melphalan-based isolated limb perfusion in locally advanced extremity soft tissue sarcomas.
    Deroose JP; Eggermont AM; van Geel AN; Burger JW; den Bakker MA; de Wilt JH; Verhoef C
    J Clin Oncol; 2011 Oct; 29(30):4036-44. PubMed ID: 21931039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan in advanced soft-tissue sarcomas: histopathological considerations.
    Issakov J; Merimsky O; Gutman M; Kollender Y; Lev-Chelouche D; Abu-Abid S; Lifschitz-Mercer B; Inbar M; Klausner JM; Meller I
    Ann Surg Oncol; 2000 Mar; 7(2):155-9. PubMed ID: 10761796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. L-[1-11C]-tyrosine PET to evaluate response to hyperthermic isolated limb perfusion for locally advanced soft-tissue sarcoma and skin cancer.
    van Ginkel RJ; Kole AC; Nieweg OE; Molenaar WM; Pruim J; Koops HS; Vaalburg W; Hoekstra HJ
    J Nucl Med; 1999 Feb; 40(2):262-7. PubMed ID: 10025833
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term outcome of isolated limb perfusion in advanced soft tissue sarcoma of the extremity.
    Olofsson R; Bergh P; Berlin O; Engström K; Gunterberg B; Hansson M; Lindnér P; Mattsson J
    Ann Surg Oncol; 2012 Jun; 19(6):1800-7. PubMed ID: 22219068
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyperthermic isolated limb perfusion, preoperative radiotherapy, and surgery (PRS) a new limb saving treatment strategy for locally advanced sarcomas.
    Stevenson MG; Seinen JM; Pras E; Brouwers AH; van Ginkel RJ; van Leeuwen BL; Suurmeijer AJH; Been LB; Hoekstra HJ
    J Surg Oncol; 2018 Jun; 117(7):1447-1454. PubMed ID: 29484661
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased shedding of soluble TNF-receptor 1 during hyperthermic TNF-α-based isolated limb perfusion.
    Grabellus F; Podleska LE; Bjerlestam S; Sheu SY; Lendemans S; Schmid KW; Taeger G
    Int J Hyperthermia; 2011; 27(1):33-41. PubMed ID: 21073296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hyperthermic isolated limb perfusion in the management of extremity sarcoma.
    Hoekstra HJ; van Ginkel RJ
    Curr Opin Oncol; 2003 Jul; 15(4):300-3. PubMed ID: 12874508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of hyperthermic isolated limb perfusion in the treatment of locally recurrent high-grade soft tissue sarcoma of the extremities.
    Farzaliyev F; Touma A; Taeger G; Steinau HU; Hardes J; Streitbürger A; Podleska LE
    World J Surg Oncol; 2020 Dec; 18(1):332. PubMed ID: 33349267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.